Clinical Cancer Research

Table of Contents

January 1, 2015 • Volume 21 • Number 1

Highlights of This Issue 1

SPECIAL FEATURES

CCR 20th Anniversary Commentary 3

Clinical Cancer Research: The 20th Anniversary

CCR Translations

4 Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake
Anja Mottok and Randy D. Gascoyne
See related article, p. 113

7 New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch
Dennis P.M. Hughes, Shivaani Kummar, and Alexander J. Lazar
See related article, p. 60

CCR New Strategies

10 New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease
Ramaprasad Srinivasan, Christopher J. Ricketts, Carole Sourbier, and W. Marston Linehan

Molecular Pathways

18 Molecular Pathways: Not a Simple Tube—The Many Functions of Blood Vessels
Brent A. Orr and Charles G. Eberhart

24 Molecular Pathways: Targeting the Kinase Effectors of RHO-Family GTPases
Tatiana Y. Prudnikova, Sonali J. Rawat, and Jonathan Chernoff

CANCER THERAPY: CLINICAL

30 Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma

39 Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Donald T. Weed, Jennifer L. Vella, Isidirinha M. Reis, Adriana C. De la fuente, Carmen Gomez, Zouakia Sargi, Ronen Nazarian, Joseph Califano, Ivan Borrello, and Paolo Serafini

49 Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Serena Di Cosimo, Stirmad Satyaynaryanan, Johanna C. Bendell, Andreas Cervantes, Mark N. Stein, Irene Bria, Desamparados Rada, Brian B. Haines, Theresa Zhang, Christopher G. Winter, Sharda Iha, Youyuan Xu, Jason Frazier, Richard A. Kleinhoffer, Ann Leighton-Swayze, Yang Song, Scott Ebbinghaus, and Jose Baselga

56 A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
See related commentary, p. 7

68 A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Kim A. Reiss, Joseph M. Herman, Marianna Zahurak, Anthony Brade, Laura A. Dawson, Angela Scardina, Caitlin Joffe, Emily Petito, Amy Hacker-Prietz, Robert J. Kinders, Lihua Wang, Alice Chen, Sarah Temkin, Naomi Horiba, Lillian L. Sui, and Nilofer S. Azad

77 First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>87</td>
<td>First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors</td>
<td>Geoffrey I. Shapiro, Eunice Kwak, Bruce J. Dezube, Murray Yule, John Aytton, John Lyons, and Danuka Mahadevan</td>
</tr>
<tr>
<td>106</td>
<td>Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma</td>
<td>Maximilian Merz, Judith Ritsch, Christina Kunz, Barbara Wagner, Sandra Sauer, Dirk Hose, Thomas Moehler, Stefan Delorme, Hartmut Goldschmidt, Christian Zechmann, and Jens Illingssan</td>
</tr>
<tr>
<td>113</td>
<td>Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma</td>
<td>Sally E. Trabucco, Rachel M. Gerstein, Andrew M. Evens, James E. Bradner, Leonard D. Shultz, Dale L. Geieter, and Hong Zhang</td>
</tr>
<tr>
<td>134</td>
<td>The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB</td>
<td>Changchun Deng, Mark Lipstein, Richard Rodriguez, Xavier O. Jirau Serrano, Christine Mcintosh, Wei-Yan H. Tsai, Andrew S. Wasmuth, Susan Jaken, and Owen A. O’Connor</td>
</tr>
<tr>
<td>146</td>
<td>CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin</td>
<td>Clara Guezzoni, Valentina Fiori, Mario Terracciano, Maria Cristina Manara, Diego Moricoli, Michela Pasello, Marika Sciandra, Giordano Nicoletti, Mara Gellini, Sabrina Dominici, Claudia Chiodoni, Pier Maria Formanati, Pier-Luigi Lollini, Mario P. Colombo, Piero Pecile, Maurizio Gianfriglia, Mauro Magnani, and Katia Scotlandi</td>
</tr>
<tr>
<td>166</td>
<td>Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer</td>
<td>Ryohei Katayama, Yuka Kobayashi, Luc Friboiulet, Elizabeth L. Lackerman, Sumie Koike, Alice T. Shaw, Jeffrey A. Engelman, and Naoya Fujita</td>
</tr>
<tr>
<td>175</td>
<td>Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma</td>
<td>Pedram Gerami, Robert W. Cook, Jeff Wilkinson, Maria C. Russell, Navnet Dhillon, Rodade N. Amaria, Rene Gonzalez, Stephen Lyle, Clare E. Johnson, Kristen M. Oelschlager, Gilchrist L. Jackson, Anthony J. Greisinger, Derek Maetzdol, Keith A. Delman, David H. Lawson, and John F. Stone</td>
</tr>
<tr>
<td>184</td>
<td>Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups</td>
<td>Diana M. Merino, Adam Shilen, Anita Villani, Malgorzata Pienkowska, Stephen Mack, Vijay Ramaswamy, David Shih, Ruth Tatevossian, Ana Novokmet, Sanaa Choufani, Rina Dvir, Myran Ben-Arush, Brent T. Harris, Eugene I. Hwang, Rishi Lulla, Stefan M. Pfister, Maria Isabel Achatz, Nada Jassal, Jonathan L. Finlay, Rosanna Weksberg, Cynthia Hawkins, Michael D. Taylor, Uri Tabori, David W. Ellison, Richard J. Gilbertson, and David Malkin</td>
</tr>
</tbody>
</table>
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>193</td>
<td>The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling</td>
<td>Chi-Pang Wen, Fanmao Zhang, Dong Liang, Christopher Wen, Jian Gu, Heath Skinner, Wong-Ho Chow, Yuanqing Ye, Xia Pu, Michelle A.T. Hildebrandt, Maosheng Huang, Chien-Hua Chen, Chao Agnes Hsiung, Min Kuang Tsai, Chwen Keng Tsao, Scott M. Lippman, and Xifeng Wu</td>
</tr>
<tr>
<td>201</td>
<td>Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression</td>
<td>Te-Sheng Chang, Yu-Chih Wu, Ching-Chi Chi, Wei-Chi Su, Pey-Jium Chang, Kam-Fai Lee, Tao-Hsin Tung, Jui Wang, Jun-Jen Liu, Shui-Yi Tung, Liang-Mou Kuo, Hong-Nerng Ho, Thai-Yen Ling, and Yen-Hua Huang</td>
</tr>
<tr>
<td>211</td>
<td>Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis</td>
<td>Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, and Wei-Ting Hwang</td>
</tr>
</tbody>
</table>

### LETTERS TO THE EDITOR

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>221</td>
<td>Diffusion-Weighted MRI for Lymphoma Staging—Letter</td>
<td>Hugo J.A. Adams and Thomas C. Kwee</td>
</tr>
<tr>
<td>222</td>
<td>Diffusion-Weighted MRI for Lymphoma Staging—Response</td>
<td>Marius E. Mayerhoefer and Markus Raderer</td>
</tr>
</tbody>
</table>

### ABOUT THE COVER

The cover shows the results of an unsupervised two-dimensional hierarchical clustering analysis of the 5,000 most variable genes classifying breast tumors into ER<sup>+</sup>, HER2<sup>+</sup>, or triple-negative (ER<sup>-</sup>, PR<sup>-</sup>, HER2<sup>-</sup>) subtypes. The analysis was performed on 800 breast tumors obtained from the Karolinska Institutet, Sweden. The RAS gene expression signature was high in the triple-negative subtype and low in the ER<sup>+</sup> subtype. For details, see the article by Di Cosimo and colleagues on page 49 of this issue.
Clinical Cancer Research

21 (1)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/21/1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.